OP
AIMT

Omni Partners’s Aimmune Therapeutics AIMT Stock Holding History

Omni Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-207,537
Closed -$7.15M – 260
2020
Q3 		$7.15M Buy
+207,537
New +$4.42M 0.51% 40

Omni Partners's AIMT Position: Q4 2020 in Review

Omni Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 207,537 shares — an estimated $7.15M sold.

Omni Partners first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $7.15M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Omni Partners reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Omni Partners sold 207,537 Aimmune Therapeutics shares in Q4 2020, an estimated $7.15M.
  • Omni Partners first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Omni Partners's Aimmune Therapeutics position peaked at $7.15M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Omni Partners's 13F filing for Q4 2020, filed 16 Feb 2021.